✨ Free AI Report
Crinetics Pharmaceuticals, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Crinetics Pharmaceuticals, Inc.
Company Research

Crinetics Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases. The company's lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment...

Analyst-debate audio for Crinetics Pharmaceuticals, Inc.

AskCyborg analysts argue the bull and bear cases for Crinetics Pharmaceuticals, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Commercial-stage endocrine specialist with first-to-market acromegaly therapy and promising late-stage pipeline backed by strong...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Specialty Endocrinology
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Crinetics Pharmaceuticals, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Crinetics Pharmaceuticals, Inc. Overview

Pro stress-test →

Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases. The company's lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. FDA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.

Strategic Profile

Pro stress-test →

Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties. The company raised approximately $350 million in gross proceeds from a January 2026 public offering to fund PALSONIFY launch and an extensive pipeline of 10+ programs in clinical development.

Competitive Landscape

Pro stress-test →

Crinetics is a clinical-stage to early-commercial pharmaceutical company in the rare endocrine diseases and endocrine-related tumors space, with paltusotine in Phase 3 development. Primary competitors are established endocrine specialists and diversified pharma companies with competing acromegaly and CAH treatments, though PALSONIFY's first-to-market oral status represents a significant competitive advantage.

Industry Context

Crinetics Pharmaceuticals, Inc. operates in Biopharmaceutical - Specialty Endocrinology.

Key facts

Founded: 2008 · Headquarters: San Diego, US · Revenue: $1.0M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Crinetics Pharmaceuticals, Inc..

  • PALSONIFY is approved for acromegaly with inadequate surgical response; paltusotine is also in clinical development for carcinoid syndrome
  • Phase 3 atumelnant trial for congenital adrenal hyperplasia initiated December 2025 following positive Phase 2 data
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Fourth quarter and full year 2025 financial results scheduled for reporting February 26, 2026
  • January 2026Completed $350 million public offering at $45.95 per share
  • +2 moreTrack every material event for Crinetics Pharmaceuticals, Inc. as it happens. Explore monitoring →
Get alerted when Crinetics Pharmaceuticals, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

SomavertPegvisomant for acromegaly→SandostatinOctreotide for acromegaly and neuroendocrine tumors→SomatulineLanreotide for acromegaly and neuroendocrine tumors→

Compare Crinetics Pharmaceuticals, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Crinetics Pharmaceuticals, Inc. operates in Biopharmaceutical - Specialty Endocrinology. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Specialty Endocrinology research →
NEW · MCP server

Ask your AI assistant about Crinetics Pharmaceuticals, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Crinetics Pharmaceuticals, Inc. and its top competitor on Cyborg Score”
“What did Crinetics Pharmaceuticals, Inc. do this quarter?”
“Is Crinetics Pharmaceuticals, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Crinetics Pharmaceuticals, Inc. do?+
Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases. The company's lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment...
What is Crinetics Pharmaceuticals, Inc.'s Cyborg Score?+
Crinetics Pharmaceuticals, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Crinetics Pharmaceuticals, Inc.'s main competitors?+
Named competitors include Somavert, Sandostatin, Somatuline. The full competitive landscape is in the AskCyborg report.
How can I get the full Crinetics Pharmaceuticals, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Crinetics Pharmaceuticals, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Crinetics Pharmaceuticals, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.